BLTE Belite Bio, Inc - ADRs
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$27.01 +0.13 (0.48%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Cayman Islands
Country of incorporation:
IPO date: 04/29/2022
Outstanding shares: 24,898,908
Average volume: 6,303
Market cap: $669,282,647
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%